Final results of the phase III URO-BCG 4 multicenter study: Efficacy and tolerance of one-third dose BCG maintenance in nonmuscle invasive bladder cancer

Anti-Cancer Drugs

Volumn 28, Issue 3, 2016, Pages 335-340

  Nouhaud, François X ^a   Rigaud, JéRome ^c   Saint, Fabien ^d   Colombel, Marc ^e   Irani, Jacques ^f   Soulie, Michel ^g   Pfister, Christian ^a,b  

^a HÔPITAL CHARLES NICOLLE   (France)

^b INSERM   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f BICÊTRE HOSPITAL   (France)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

bacillus Calmette Guerin maintenance; bladder cancer; recurrence; side effects

Indexed keywords

BCG VACCINE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLADDER DISEASE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHILL; CONTROLLED STUDY; CYSTITIS; DRUG EFFICACY; DRUG INSTILLATION; DRUG TOLERANCE; FEMALE; FEVER; FLU LIKE SYNDROME; GRANULOMATOSIS; HEMATURIA; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; LEUKOCYTURIA; LUNG INFECTION; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NON MUSCLE INVASIVE BLADDER CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SEPSIS; SIDE EFFECT; SYSTEMIC DISEASE; TUMOR VOLUME; CLINICAL TRIAL; DRUG ADMINISTRATION; INTRAVESICAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; TUMOR INVASION; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; URINARY BLADDER NEOPLASMS;

EID: 85000347732     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000456     Document Type: Article

References (21)

1. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49:466-475
2. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical BCG reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168:1964-1970
3. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003; 169:90-95
4. Pfister C, Roupret M, Neuzillet Y, Larre S, Pignot G, Quintehs H, et al. Recommendations onco-urology 2013-2016: urothelial tumors. Prog Urol 2013; 24 (Suppl 2):105-125
5. Babjuk M, OosterlinckW, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, et al. EAU guidelines on non invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59:997-1008
6. Saint F, Irani J, Patard JJ, Salomon L, Hoznek A, Zammattio S, et al. Tolerability of BCG maintenance therapy for superficial bladder cancer. Urology 2001; 57:883-888
7. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized South West Oncology Group study. J Urol 2000; 163:1124-1129
8. Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Final results of an EORTC-GU cancers group randomized study of maintenance BCG in intermediate and high risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013; 63:462-472
9. Martinez-Pineiro JA, Flores N, Isorna S, Solsona E, Sebastián JL, Pertusa C, et al. or CUETO (Club Urológico Español de Tratamiento Oncológico). Longterm follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 2002; 89:671-680
10. Fernandez-Gomez J, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, Hernandez R, et al. Club Urológico Español de Tratamiento Oncológico (CUETO). Prognostic factors in patients with non-muscle-invasive bladder cancer treated with BCG: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008; 53:992-1001
11. Pfister C, Kerkeni W, Rigaud J, Legal S, Saint F, Colombel M, et al. Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study. Int J Urol 2015; 22:53-60
12. Saint F, Irani J, Salomon L, Legrand P, Abbou CC, Chopin D. Urinary leukocytes as a new prognostic marker of therapeutic response and of adverse effects associated with the maintenance treatment with endovesical BCG, for the prophylaxis of superficial bladder tumors. Prog Urol 2001; 11:1242-1250
13. Leibovici D, Zisman A, Chen-Levyl Z, Cypele H, Siegel YI, Faitelovich S, Lindner A. Elevated prostate specific antigen serum levels after intravesical instillation of bacillus Calmette-Guerin. J Urol 2000; 164:1546-1549
14. Ratliff TL, Haaff EO, CatalonaWJ. Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer. Clin Immunol Immunopathol 1986; 40:375-379
15. De Boer EC, De Jong WH, Steerenberg PA, Aarden LA, Tetteroo E, De Groot ER, et al. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette- Guerin in superficial bladder cancer. Cancer Immunol Immunother 1992; 34:306-312
16. Van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono A. Maintenance BCG for Ta-T1 bladder tumors is not associated with increased toxicity: results from a EORTC of cancer genito-urinary group phase III trial. Eur Urol 2003; 44:429-434
17. Pagano F, Bassi P, Piazza N, et al. Improving the efficacy of BCG immunotherapy by dose reduction. Eur Urol 1995; 27:19-22
18. Ojea A, Nogueira JL, Solsona E, Flores N, Gómez JM, Molina JR, et al. A multicenter, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose BCG (27 mg) versus very low-dose BCG (13.5 mg) versus mitomycin C. Eur Urol 2007; 52:1398-1406
19. Takeda T, Kikuchi E, Yuge K, Matsumoto K, Miyajima A, Nakagawa K, Oya M. Discontinuance of bacillus Calmette-Guerin instillation therapy for non muscle-invasive bladder cancer has negative effect on tumor recurrence. Urology 2009; 73:1318-1322
20. Decobert M, LaRue H, Harel F, Meyer F, Fradet Y, Lacombe L. Maintenance bacillus Calmette-Guerin in high-risk nonmuscle-invasive bladder cancer: how much is enough? Cancer 2008; 113:710-716
21. Blah M, Gobet F, Dugardin F, Catovic B, Loisel F, Pfister C. Elevation of total PSA after intravesical BCG instillations: granulomatous prostatitis or prostatic adenocarcinoma? Prog Urol 2008; 18:108-113